Navigation Links
PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results
Date:4/27/2009

31 $262,690 $214,566 ======== ======== ======== Cash and marketable securities $99,512 $51,918 $53,313 Working capital $141,331 $146,535 $165,437 Total assets $1,105,560 $948,071 $859,638 Short-term borrowings $57,100 $66,474 $13,656 Long-term debt $229,360 $3,465 $38,443 Stockholders' equity $360,210 $428,091 $397,266 PAREXEL International Corporation Consolidated Condensed Statement of Income (In thousands, except per share data) Unaudited Nine Months Ended ------------------------------------------ March 31, 2009 ------------------------------------------ As Reported Adjustments Adjusted ----------- ----------- -------- Service revenue $803,349 $803,349 Reimbursement revenue 151,165 151,165 ------- ------- Total revenue 954,514 954,514 Costs and expenses: Direct costs 514,440 514,440 Reimbursable out-of-pocket expenses 151,165 151,165 Selling, general and administrative 178,785 178,785 Depreciation 31,765 31,765 Amortization 7,237 7,237 Sp
'/>"/>
SOURCE PAREXEL International Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. PAREXEL Receives BioSingapore Award for Best Performing CRO
2. PAREXEL Experts to Address Benefits of Rigorous Early Phase Development at Annual ASCPT Meeting
3. PAREXEL Expert to Address Value of Incorporating Asia Into Global Clinical Development at BioMedical Asia 2009
4. PAREXEL Experts to Present Leading Insights at Drug Information Association 21st Annual Euromeeting
5. PAREXEL Appoints Josephine Hoppe to Chief Information Officer
6. PAREXEL International to Present at the 27th Annual JP Morgan Healthcare Conference
7. PAREXEL Receives Best CRO Award from Scrip
8. PAREXEL Establishes Alliance with SITS Network of Clinical Sites Specializing in Stroke Studies
9. PAREXEL Expands Pioneering Asian Ethnobridging Expertise
10. PAREXEL Expert to Address Key Aspects of Conducting Clinical Trials in China at 7th Annual Partnerships in Clinical Trials Congress
11. PAREXEL International to Present at Oppenheimer 19th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014 iLab Solutions, the global leader ... Siri Bryant as the new Director of Institutional Implementations ... Implementations. These two new leadership positions were created to ... ensuring that iLab continues to meet the needs of ... years, iLab has been deployed at over 450 core ...
(Date:12/19/2014)... , Dec. 18, 2014  Decision Resources Group finds ... biomaterial market will grow moderately through 2023 as the ... growing awareness of dental biomaterials all spur procedure volumes. ... as China and ... dental procedures within reach for a larger proportion of ...
(Date:12/17/2014)... 16, 2014 The Activated Carbon ... which is why IBISWorld updated its original industry research ... benefit from an intensified focus on environmental policy. Over ... emission standards for power plants and a range of ... IBISWorld Industry Analyst Sarah Kahn, “a range of downstream ...
(Date:12/17/2014)... Ipsen Biopharmaceuticals, Inc., an affiliate ... IPSEY), today announced that Somatuline® Depot® (lanreotide) ... approved by the U.S. Food and Drug Administration ... (GEP-NETs) in adult patients with unresectable, well or ... improve progression-free survival (PFS). , “The approval of ...
Breaking Biology Technology:iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 3Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
... Feb. 6, 2012  Auxilium Pharmaceuticals, Inc. (Nasdaq: ... announced the appointment of two executive officers, effective ... Vice President, Chief Administrative Officer and General Counsel, ... Vice President, Sales. "The leadership appointments ...
... 2012 Ikaria, Inc., a critical care company focused on ... needs of critically ill patients in the hospital and ICU ... will present at the 14th Annual BIO CEO & Investor ... 13, 2012 at 3:30 p.m. EST in the Park South ...
... , a Manchester team lead by Nobel laureates Professor Andre ... dimension in graphene research. Their research shows a transistor that ... next silicon. Graphene one atomic plane of ... from electronic to chemical and from optical to mechanical. ...
Cached Biology Technology:Auxilium Announces Appointments to Enhance Leadership Team 2Auxilium Announces Appointments to Enhance Leadership Team 3Auxilium Announces Appointments to Enhance Leadership Team 4Auxilium Announces Appointments to Enhance Leadership Team 5Ikaria® to Present at 14th Annual BIO CEO & Investor Conference 2Graphene electronics moves into a third dimension 2
(Date:12/10/2014)... N.C. , Dec. 9, 2014  Valencell, a ... it is seeing a staggering demand from its licensees ... the Company revealed, is not solely coming from fitness ... as well. "A wearable is only as ... result, accuracy is the ultimate driver in long-term mass ...
(Date:12/10/2014)... , Dec. 08, 2014 Research and Markets ... addition of the "Biometrics Market in Japan ... http://photos.prnewswire.com/prnh/20130307/600769 The ... such as rural banking and upgradation of the ... witnessed in the market. Besides the aforementioned projects, ...
(Date:12/5/2014)... 4, 2014  Tute Genomics, a leader in cloud-based ... Series A1 funding led by UK-based Eurovestech. Peak Ventures ... the investment round. "We are at a ... next-generation sequencing and seeks new approaches for the diagnosis, ... , MD MBA, and CEO of Tute Genomics. "One ...
Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
... a gene implicated in human cancers, researchers from Whitehead Institute ... online issue of Science. , MicroRNAs are tiny snippets of ... the gene's messenger RNA (which copies DNA information and starts ... microRNA was discovered in 1993, in worms. It took seven ...
... digest cellulose, but the human process of producing ethanol ... is the sluggish rate at which the cellulose enzyme ... are then fermented into ethanol. , To help unlock ... molecular simulations at the San Diego Supercomputer Center (SDSC), ...
... parents, 8 million cases of acute middle ear infections every ... trips to the pediatrician. But new research from a collaboration ... all that. , In the March 23 issue of ... Jude show that middle ear infections in mice can be ...
Cached Biology News:MicroRNA helps prevent tumors 2MicroRNA helps prevent tumors 3Meeting the ethanol challenge: Scientists use supercomputer to target cellulose bottleneck 2Meeting the ethanol challenge: Scientists use supercomputer to target cellulose bottleneck 3Viral protein is an effective preventative against infection 2
Mouse monoclonal antibody raised against a partial recombinant QARS. NCBI Entrez Gene ID = QARS...
96-well format (For processing samples on microplate-size MALDI target plates such as those from Bruker, Shimadzu, Thermo, and PerkinElmer) Packaging: 2 / pack...
... mixing devices. Stepping motors device is maintenance ... durable shaker to provide a uniform motion ... nature. Regulated action scale for all modes. ... control time, continuous time, action scale and ...
Mouse monoclonal antibody raised against a partial recombinant STAU2. NCBI Entrez Gene ID = STAU2...
Biology Products: